- Home
- CHEK vs ADTX Comparison
CHEK vs ADTX Comparison
Compare CHEK & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHEK
- ADTX
- Stock Information
- Founded
- CHEK 2004
- ADTX 2017
- Country
- CHEK Israel
- ADTX United States
- Employees
- CHEK N/A
- ADTX N/A
- Industry
- CHEK Medical Electronics
- ADTX Biotechnology: Pharmaceutical Preparations
- Sector
- CHEK Health Care
- ADTX Health Care
- Exchange
- CHEK Nasdaq
- ADTX Nasdaq
- Market Cap
- CHEK 4.5M
- ADTX 5.3M
- IPO Year
- CHEK 2015
- ADTX 2020
- Fundamental
- Price
- CHEK $0.81
- ADTX $5.00
- Analyst Decision
- CHEK
- ADTX
- Analyst Count
- CHEK 0
- ADTX 0
- Target Price
- CHEK N/A
- ADTX N/A
- AVG Volume (30 Days)
- CHEK 52.9K
- ADTX 8.1M
- Earning Date
- CHEK 05-14-2025
- ADTX 05-19-2025
- Dividend Yield
- CHEK N/A
- ADTX N/A
- EPS Growth
- CHEK N/A
- ADTX N/A
- EPS
- CHEK N/A
- ADTX N/A
- Revenue
- CHEK N/A
- ADTX $133,985.00
- Revenue This Year
- CHEK N/A
- ADTX $95.61
- Revenue Next Year
- CHEK N/A
- ADTX $1,584.79
- P/E Ratio
- CHEK N/A
- ADTX N/A
- Revenue Growth
- CHEK N/A
- ADTX N/A
- 52 Week Low
- CHEK $0.56
- ADTX $4.11
- 52 Week High
- CHEK $3.04
- ADTX $35,000.00
- Technical
- Relative Strength Index (RSI)
- CHEK 47.11
- ADTX 33.28
- Support Level
- CHEK $0.77
- ADTX $4.17
- Resistance Level
- CHEK $0.86
- ADTX $7.69
- Average True Range (ATR)
- CHEK 0.08
- ADTX 1.92
- MACD
- CHEK 0.00
- ADTX 0.36
- Stochastic Oscillator
- CHEK 41.46
- ADTX 10.10
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.
About ADTX Aditxt Inc.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.